Rafael Holdings, Inc. (NYSE:RFL) Sees Large Growth in Short Interest

Rafael Holdings, Inc. (NYSE:RFL) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 133,570 shares, a growth of 90.8% from the June 15th total of 70,015 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 303,935 shares, the days-to-cover ratio is currently 0.4 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, May 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rafael presently has a consensus rating of “Sell”.

Rafael Stock Up 0.4%

Shares of Rafael stock traded up $0.01 on Thursday, hitting $2.35. The stock had a trading volume of 83,792 shares, compared to its average volume of 132,730. The stock has a market cap of $122.20 million, a price-to-earnings ratio of -3.46 and a beta of 0.29. Rafael has a twelve month low of $1.12 and a twelve month high of $3.96. The business’s 50 day moving average is $2.03 and its two-hundred day moving average is $1.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Rafael by 10.5% during the third quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock worth $1,897,000 after buying an additional 133,024 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Rafael by 25.4% in the fourth quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock valued at $526,000 after acquiring an additional 90,417 shares in the last quarter. Citadel Advisors LLC increased its position in Rafael by 132.3% during the third quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock worth $99,000 after acquiring an additional 41,335 shares during the period. Cable Car Capital LP bought a new position in Rafael during the second quarter worth about $173,000. Finally, Marshall Wace LLP acquired a new stake in Rafael in the 2nd quarter worth about $50,000. 11.30% of the stock is owned by institutional investors and hedge funds.

About Rafael

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.